Inova Schar Cancer Institute

Clinical research site in Fairfax, Virginia · Inova Schar Cancer (A dept of Fairfax Hospital), 8081 Innovation Park Dr, Fairfax, VA 22031 · (571) 472-4724 · Website

Part of Inova Schar Cancer Institute

As of July 2026, 68 paid clinical trials are recruiting at Inova Schar Cancer Institute in Fairfax, Virginia. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Inova Schar Cancer Institute (68)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

38 locations incl. Anchorage

Sponsor: Incyte Corporation

Sex: Female·Age: 18+

Code: NCT07214779·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for Metastatic Castration-resistant Prostate Cancer (mCRPC)

57 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

58 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

65 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

for Urothelial Carcinoma

144 locations incl. Gilbert

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04879329·Phase 2·Recruiting·Listed May 2021

Apply to this trial

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

for Glioblastoma

32 locations incl. Phoenix

Sponsor: NovoCure GmbH

Sex: All·Age: 18+

Code: NCT06556563·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

for Immune Thrombocytopenia

10 locations incl. Glendale

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07104565·Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

for Colorectal Cancer

22 locations incl. Huntsville

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07023289·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Study of XB010 in Subjects With Solid Tumors

for Locally Advanced or Metastatic Solid Tumors

16 locations incl. Irvine

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06545331·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

for Head and Neck Squamous Cell Carcinoma (HNSCC)

14 locations incl. Los Angeles

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06769698·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

for Anemia, Sickle Cell

18 locations incl. Birmingham

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06481306·Phase 1, Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

for Advanced Or Metastatic Merkel Cell Carcinoma

18 locations incl. Los Angeles

Sponsor: TuHURA Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT06947928·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Phase 2/3 Study in Adult and Adolescent Participants With SCD

for Sickle Cell Disease

13 locations incl. New Haven

Sponsor: Pfizer

Sex: All·Age: 12+

Code: NCT05431088·Phase 2, Phase 3·Recruiting·Listed Jun 2022

Apply to this trial

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

for Advanced Solid Tumor

16 locations incl. Irvine

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06244485·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

23 locations incl. Tucson

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

for Malignant Melanoma

5 locations incl. Springdale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06961006·Phase 2·Recruiting·Listed May 2025

Apply to this trial

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

for Breast Neoplasms

5 locations incl. Aurora

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06686394·Phase 1, Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

for Colorectal Cancer

9 locations incl. New Haven

Sponsor: Criterium, Inc.

Sex: All·Age: 18+

Code: NCT06992258·Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

for EGFR Inhibitor-associated Rash

6 locations incl. Hot Springs

Sponsor: Azitra Inc.

Sex: All·Age: 18+

Code: NCT06830863·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center

for Cancer

1 location in Fairfax

Sponsor: Inova Health Care Services

Sex: All·Age: 35 - 85·Accepts healthy volunteers

Code: NCT07485322·Recruiting·Listed Mar 2026

Apply to this trial

Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture

for Hot Flashes

1 location in Fairfax

Sponsor: Inova Health Care Services

Sex: Male·Age: 18+

Code: NCT07335224·Recruiting·Listed Jan 2026

Apply to this trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

for Advanced Hepatocellular Carcinoma

138 locations incl. Berkeley

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT07166406·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

456 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

643 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

for Extensive Stage Lung Small Cell Carcinoma

273 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04402788·Phase 2, Phase 3·Recruiting·Listed May 2020

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

430 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

357 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

316 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting·Listed May 2025

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

328 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Showing the 40 most relevant of 68 recruiting trials at this site. Browse all with filters →

More research sites in Fairfax

NEXT Virginia (72 trials)
Virginia Cancer Specialists (65 trials)
NEXT Oncology Virginia (29 trials)
NEXT Oncology (25 trials)
Virginia Cancer Specialists, PC (17 trials)
Inova Fair Oaks Hospital (14 trials)
Re:Cognition Health (7 trials)
Inova Schar Cancer (6 trials)
Inova Fairfax Hospital (5 trials)
NEXT Oncology - Virginia (5 trials)

Explore more

Paid clinical trials in Fairfax, VA · Virginia clinical trials